Amit Garg

Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice

Amit Garg, Joseph P. Balthasar · Journal of Pharmacokinetics and Pharmacodynamics · 2007 · 314 citations

Systems Pharmacology, Knockout Mouse, Physiologically-based Pharmacokinetic +10

Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials

Alexa B. Kimball, Gregor B. E. Jemec, Christopher J. Sayed et al. · The Lancet · 2024 · 128 citations · Full text

Moderate-to-severe Hidradenitis Suppurativa, Be Heard Ii, Be Heard +3

HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Manish A. Shah, Rui‐Hua Xu, Yung‐Jue Bang et al. · Journal of Clinical Oncology · 2017 · 116 citations

Investigation of the Influence of FcRn on the Distribution of IgG to the Brain

Amit Garg, Joseph P. Balthasar · The AAPS Journal · 2009 · 104 citations · Full text

Cognitive Neuroscience, Neurophysiology, Medicine +8

A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer

Y-K Kang, Sun Young Rha, Pierfrancesco Tassone et al. · British Journal of Cancer · 2014 · 94 citations · Full text